



# SHUKRA

PHARMACEUTICALS LTD.

01<sup>st</sup> February, 2023

To  
The General Manager-Listing  
Corporate Relationship Department  
BSE Limited, Ground Floor,  
P.J. Towers, Dalal Street,  
Mumbai-400001

Scrip Code: 524632

Dear Sir/Madam,

Sub: Intimation of meeting of the Board of Directors of the Company under Regulation 29(1) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the "SEBI Listing Regulations").

Notice is hereby given that the pursuant to the Regulation 29 read with other applicable Regulation of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, the Meeting of the Board of Directors of the Company will be held on 14<sup>th</sup> February, 2023 at 03:00 p.m. at the Registered Office of the Company to transact the following business:

1. To consider and approve Unaudited Financial Results for the Quarter and Nine months ended December 31, 2022.
2. To appoint CS Rupal Patel, Practicing Company Secretary as Secretarial Auditor of the Company for the F.Y. 2022-23.
3. Any other business with the permission of chair.

In terms of the Company's Code of Conduct for Prevention of Insider Trading, the "Trading Window" for dealing in securities of the Company has been closed from January 01, 2023 till the end of 48 hours after the declaration of the Financial Results of the Company for the quarter and nine months ended December 31, 2022.

Please take the same on record.

Thanking you,

Yours faithfully

For Shukra Pharmaceutical Limited

  
Bhoomiben Patel  
Director  
(DIN: 08316893)

**CIN : L24231GJ1993PLC019079**